首页> 外文期刊>Trends in Biotechnology >Structural genomics of GPCRs
【24h】

Structural genomics of GPCRs

机译:GPCR的结构基因组学

获取原文
获取原文并翻译 | 示例
       

摘要

G protein-coupled receptors (GPCRs) are targets for 60-70% of drugs in development today. Traditionally, the drug discovery process has relied on screening of chemical compounds to identify novel and more-efficient drug molecules. Structure-based drug design, however, provides a targeted approach but has been severely hampered by limited knowledge of high-resolution structures of GPCRs owing to the difficulties encountered in their expression, purification and crystallization. In addition to individual laboratories studying specific GPCRs, structural genomics initiatives have been established as large networks with a wide range of expertise in protein expression, purification and crystallography. Several of these national and international consortia have included GPCRs in their programs. Milligram quantities of GPCRs can now be expressed in several expression systems and purified to high homogeneity. However, success in crystallization still requires major technological improvement.
机译:G蛋白偶联受体(GPCR)是当今开发中60-70%药物的目标。传统上,药物发现过程依赖于化学化合物的筛选来鉴定新颖和更有效的药物分子。然而,基于结构的药物设计提供了针对性的方法,但是由于在表达,纯化和结晶方面遇到的困难,GPCR的高分辨率结构的有限知识受到严重阻碍。除了研究特定GPCR的各个实验室之外,结构基因组计划也已建立为大型网络,在蛋白质表达,纯化和晶体学方面拥有广泛的专业知识。这些国家和国际财团中有几个将GPCR纳入了他们的计划。现在可以在几个表达系统中表达毫克量的GPCR,并纯化至高度均一。然而,结晶的成功仍然需要重大的技术改进。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号